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The aim of this study was to evaluate the potential of different types of sialyl Lewis X-conjugated liposomes as competitive inhibitors for
tumour cell adhesion to endothelial E-selectin.
Sterically stabilised liposomes with the sLeX ligand at the terminal end of the polyethyleneglycol (PEG) chain, as well as vesicles that had
the ligand embedded within the PEG-layer, were compared to ligand-bearing liposomes without sterical stabilisation.
First, 14 different tumour cell lines were characterised for their expression of sialyl Lewis X and/or A. Tumour cell adhesion was
characterised in three static assays in vitro using: (i) immobilised E-selectin, (ii) CHO cells, transfected to express E-selectin and (iii) human
umbilical vein endothelial cells (HUVEC).
Sterically stabilised liposomes with the ligand at the terminal end of the polyethylene chain were the most effective inhibitors in all three
assays and inhibited the adhesion of HT29 colon- and Lewis lung (LL) carcinoma cells by about 60–80%. The binding was not affected by a
PEG-coating of the liposomes. Sterical stabilisation, on the other hand, completely prevented macrophage uptake (J774 cell line)
independently of the presence of the ligand, while plain liposomes were taken up in an amount of 5.4 nmol liposomal lipids/106
macrophages.
D 2003 Elsevier B.V. All rights reserved.Keywords: Adhesion; E-selectin; Sialyl LewisX; Sterically stabilised glycoliposome1. Introduction
Blood-borne metastasis is a complex multi-step process
that includes, among others, the essential extravasation of
circulating tumour cells from the blood system, followed by
the invasion into the organ at the site of metastasis. These0005-2736/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamem.2003.10.014
Abbreviations: CH, cholesterol; DCP, dicetylphosphate; DSPE, di-
stearylglycerophosphatidylethanolamine; EDTA, ethylenediamine tetraace-
tate; HPTS, 1-hydroxypyrene-3,6,8-trisulfonic acid; HUVEC, endothelial
cells from human umbilical vein; LUVET, large unilamellar vesicles made
by extrusion technique; MLV, multilamellar vesicles; MPS, mononuclear
phagocyte system; PBS, phosphate-buffered saline solution; PC, egg
phosphatidylcholine; PE, phosphatidylethanolamine; PEG, polyethylene-
glycol; PEG2000DSPE, N-(O-methoxy-polyethylene glycyl)-1,2-distearyl-
s,n-glycero-3-phosphatidylethanolamine; RT, room temperature; S.D.,
standard deviation; sLeA, sialyl LewisA; sLeX, sialyl LewisX
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E-mail address: rzeisig@mdc-berlin.de (R. Zeisig).steps involve interactions of different homotypic and het-
erotypic cell–cell adhesion molecules expressed on circu-
lating tumour cells and/or on blood vessel cells.
A possible concept for the prevention of metastasis is to
target the circulating tumour cells and to block the ligands at
their surface, which are necessary to adhere to the endothe-
lial surface. Conversely, the competitive inhibition of recep-
tors at the endothelial site would also be possible.
In this context, E-selectin plays a crucial role [1,2]. This
membrane protein is exclusively expressed on activated
endothelial cells and is involved in the first step of the
adhesion cascade taking place on the endothelial cell surface
in adhesion processes of leukocytes [3] and metastatic
tumour cells [4,5]. E-selectin recognises specifically the
tetrasaccharides sialyl LewisX (sLeX) and A (sLeA), which
are expressed either protein- or lipid-bound on the surface of
different tumour cells and of leukocytes [6–8].
The inhibition of the E-selectin-mediated adhesion is
discussed as a possibility to prevent or (at least) to reduce
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tions of high risk, e.g. during tumour surgery, when the
number of circulating tumour cells may be increased, but
has been investigated so far by only a few groups [9–14].
If the endothelial membrane is used as a target, for
example to transport a pro-drug [9,13] or to deliver anti-
sense oligonucleotides [15] to the endothelium, several
different opportunities can also be exploited to prevent or
to reduce tumour cell adhesion. This includes blocking of
selectins [11], as well as the suppression of integrin [16,17]
or VCAM-1 expression [15]. The inhibition of tumour
neovascularisation [18] has also been used for that purpose
[8].
Useful tools for a competitive blockade of the endothelial
E-selectin, and thus for an inhibition of the initial step of
tumour cell adhesion, are specific antibodies [16], peptides
[11] and liposomes equipped with specific ligands
[11,15,19,20]. For this purpose, carbohydrates like sLeX, a
tetrasaccharide that selectively recognises the carbohydrate
binding region of E-selectin, can be conjugated to the
liposomal surface to obtain glycoliposomes with inhibitory
potential [11,14,15,19]. Liposomes, compared to the free
ligand, have the advantage of forming ligand clusters on
their surface. This enables the glycoliposomes to a multi-
valent-ligand adhesion, which finally promotes the binding
efficacy strongly between a vesicle and the receptor cluster
on the cell surface [21].
In continuing our previous studies [21,22], we evaluated
in this study different types of sLeX-liposomes as inhibitors
of E-selectin-mediated tumour cell adhesion in different
static assays in vitro. The results of this study demonstrated
a strong inhibition effect on the binding of different cell
lines in vitro, especially for sterically stabilised liposomes
with the ligand at the distal end of the polyethyleneglycol
(PEG) chain.2. Materials and methods
2.1. Materials
Egg phosphatidylcholine (PC) was obtained from Lipoid
GmbH (Ludwigshafen, Germany), DMPE from Sigma
(Taufkirchen, Germany) and EDTA from Serva (Heidelberg,
Germany). sLeX-DMPE was synthesised as described pre-
viously [21], whereas sLeX-PEG2000DSPE, was custom-
synthesised by SYNTHESOME mbH (Munich, Germany).
3-[N-methoxy-(polyethylene-glycol2000)]-phosphatidyletha-
nol-amine (PEG-DSPE) was purchased from Sygena LTD
(Liestal, Switzerland). HPTS, 1-hydroxypyrene-3,6,8-trisul-
fonic acid, was obtained from Molecular Probes (Eugene,
OR, USA), whereas 51Cr-sodium chromate was a product of
Amersham Pharmacia (Buckinghamshire, England). The
pCDM8 expression vector containing the hE-selectin
cDNA, the pSV2-neo vector with the gene for neomycin
phosphotransferase, recombinant human E-selectin, the anti-human E-selectin monoclonal antibody BBA2 as well as the
FITC-conjugated anti-hE-selectin antibody BBA21 were
received from R&D Systems GmbH (Wiesbaden, Ger-
many). The antibiotic G418 was a product of Invitrogen
(Paisley, UK). The anti-human sLeA mouse monoclonal
antibody KM231 as well as anti-human sLeX mouse mono-
clonal antibody KM93 were obtained from Calbiochem (La
Jolla CA, USA), the FITC-conjugated mouse anti-h sLeX
monoclonal antibody 2H5 from PharMingen Europe and the
anti-mouse IgG specific Cyk2-antibody were purchased
from Dianova (Hamburg, Germany).
Media, sera and other chemicals for cell culturing were
purchased from Life Technologies (Karlsruhe, Germany).
2.2. Preparation and characterisation of liposomes
The different compositions of liposomes are shown in
Table 1. Vesicles were prepared as follows: first, appropriate
volumes of stock solutions of indicated components in
CH2Cl2/MeOH (7:3) were mixed, the solvent evaporated
to produce a thin lipid film which was then dispersed in PBS
buffer (156 mM; including 6.8 mM Ca2 + and Mg2 +; pH
7.4, Life Technology, #14040) to obtain a concentration of
total lipid between 7 and 9 mg/ml. The suspension was
shaken for 12 h at room temperature to prepare multi-
lamellar vesicles (MLV). Large unilamellar liposomes
(LUVET) were generated from the MLV by repeated
extrusion through polycarbonate filters of 100 nm pore size
using a LiposoFastk Basic System (Avestin, Inc., Ottawa,
Canada). Vesicle size was determined by dynamic light
scattering using a Coulter Counter N4 MD (Coulter Elec-
tronics Inc., Hialeah, USA). Liposomes were used if the
vesicles had an unimodal diameter between 100 and 120 nm
with a polydispersity index of 0.20 or lower.
The final lipid concentration of the liposomal suspension
was determined by phosphatidylcholine quantification using
HPTLC as described previously [23].
2.3. Transfection of E-selectin cDNA in CHO cells and
isolation of a stable CHOtransf cell line
Chinese hamster ovary (CHO) cells were grown at 37 jC
with 5% CO2 in Dulbecco’s modified Eagle medium
(DMEM), supplemented with 10% foetal calf serum
(FCS), 2 mM L-glutamine, 100 U/ml penicillin/streptomy-
cin, and 1 mM sodium pyruvate. Cells (5 105) were re-
seeded on 60-mm plates 1 day before transfection.
The TransFast Transfection Reagent was used to trans-
fect CHO cells with a full-length 2.7 kb hE-selectin cDNA
cloned in pCDM8 expression vector. A pSV2-neo vector
containing the gene for neomycin phosphotransferase,
which confers resistance to the antibiotic G418 was cotrans-
fected. After 48 h of transfection, cells were trypsinised and
replated in medium containing G418. About 2 weeks later,
individual colonies were isolated and grown again in the
presence of G418.
Table 1
Composition of liposomes used for inhibition of tumour cell adhesion
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FACS sorting: FITC-conjugated anti-hE-selectin antibody
BBA21, diluted 1:20, was added to 107 cells and incubated
for 1 h at 4 jC. Unbound antibody was removed by washing
three times with PBS containing 1% FCS. CHO cells with a
fluorescence intensity comparable to that of activated
HUVECs, were sorted out by FACS analysis, collected in
500 Al fractions and grown in DMEM in a CO2 incubator at
37 jC for 2 weeks. FACS sorting was repeated three times.
E-selectin expression was proven by immune fluorescence
microscopy using the BBA21 antibody.
2.4. Cell culture and radiolabelling
CHOtransf and HT29 colon carcinoma cells were grown
in DMEM, whereas all other tumour cells used in this study
(Table 3) were kept in RPMI media. All the media were
supplemented with 10% FCS.
HUVECs were isolated from human umbilical veins by
treatment with a-chymotrypsin (0.2% w/v) as reported
previously [24]. They were used within four passages.
Tumour cells were radiolabelled by incubating the cells
for 4 h at 37 jC with 1–1.5 MBq/ml 51Cr-sodium chromate,
washed three times by centrifugation (10 min, 1400 g)
and resuspended in phosphate buffered saline containing 2
mM Ca2 + (Ca-PBS).
2.5. Characterisation of tumour cell ligand expression by
immune fluorescence
Tumour cells were fixed on glass slides with 5% formalin
in PBS for 5 min at room temperature, washed and incu-
bated with 50 Al of monoclonal antibodies KM 231 (anti-
sLeX) or 2H5, a FITC-labelled anti-sLeX antibody (Phar-
Mingen International), diluted 1:50 (PBS/0.3% BSA) at
room temperature for 1 h.If KM231 was used, cells were then incubated with 50
Al of fluorescently labelled secondary antibodies Cyk2 for
1 h at 4 jC to visualise anti-mouse IgG. Cells were finally
covered with Aqua-Poly/Mount (Polysciences Inc., War-
rington, USA).
Immune microscopy was performed and micrographs
taken with a Axiophot photo microscope (Zeiss), using the
Axio Vision 3.1 software.
2.6. Cellular uptake of liposomes by J774 macrophages
These experiments were done according to Ref. [25] as
described recently [26]. Briefly: 2 104 J774 mouse
macrophages (DMSZ, Hannover, Germany) were seeded
per well in a 96-well FluoroNunck microtiter plate
(Nunc A/S, Roskilde, Denmark). After 8 h, cells were
incubated at 37 jC for 1, 3, 6 and 21 h with plain
liposomes A, sterically stabilised liposomes B and sLeX-
bearing liposomes E, all containing 30 mM HPTS, and
diluted with RPMI/10% FCS to a final concentration of
50 AM. Cells were additionally incubated for control pur-
poses with the liposomes at 4 jC for 4 h to determine the
non-specific binding of vesicles and also co-incubated with a
solution of HPTS in medium (100 mM) for 24 h to character-
ise the fluorescence properties of HPTS in the low pH
compartment.
The amount of cell associated HPTS was determined
from a standard curve of free HPTS in PBS buffer (15–
1500 pmol/ml), pH 7.4.
Differentiation between general uptake and internalised
marker was calculated using the equation mintern =Rexp/
Rpin 100 with mintern, cellular internalised liposomal HPTS
in percentage of total uptake; Rpin, fluorescence ratio
(450:415 nm) in cells after uptake of free HPTS; and Rexp,
fluorescence ratio (450:415 nm) determined for liposomal
HPTS which was taken up by the cells.
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concentration of liposomal OPP found associated with cells,
exploring the ratio of HPTS/OPP (mmol/mol) for each
individual liposomal preparation used. These results were
corrected for non-specific uptake.
2.7. Tumour cell adhesion assays
2.7.1. Adhesion to immobilised E-selectin
Forty microliters of recombinant human E-selectin (5 Ag/
ml Ca2 +-PBS) were immobilised per well on 96-well
microtiter plates overnight at room temperature (RT). After
a single washing step with 50 Al of Ca2 + containing TRIS
buffer (Ca-TRIS), the non-specific binding sites were
blocked with BSA/Ca-Tris (2%) for 2 h at RT and finally
washed again two times with 50 Al/well Ca-TRIS.
Then, 10 Al with 105 radiolabelled tumour cells were
added to each well for determination of adhesion rates.
2.7.2. Adhesion to endothelial cells and to transfected CHO
cells
HUVEC or CHOtransf target cells were grown in a 96-
well microtiter plate (Nunc) until near confluence (HUVEC:
2–3 104 cells/well; CHOtransf: 3.5 104 cells/well).
HUVECs were additionally co-incubated with 0.5 ng
TNFa/well for 4 h/37 jC to stimulate E-selectin expression.
Only results of such experiments were taken into account in
which an at least 4-fold higher binding of tumour cells to
activated HUVEC than to non-activated target cells were
obtained. Wild-type CHO cells (wt CHO) were used as
control for adhesion to CHOtransf.
After washing the cells twice with Ca-Tris buffer, tumour
cell binding was determined as described for the E-selectin
assay above.
As control for specificity, the binding of tumour cells to
non-stimulated HUVEC or to wt CHO cells was addition-
ally determined, and subtracted to eliminate the non-specific
binding.
2.7.3. Inhibition of adhesion
Adhesion of tumour cells was followed as described
above, but before addition of radiolabelled tumour cells,
the inhibitors EDTA (10 mM) for non-specific blocking of
binding, monoclonal antibody BBA2, specific for E-selectin
(11–33 ng/well), or liposomes with or without 3.5 nmol
sLeX-ligand were added to each well with immobilised E-
selectin, HUVEC or CHO cells. After tumour cell addition,
the total volume was equalised with medium to 40 Al/well.
After 1 h of incubation at RT, unbound cells were washed
away two times with 50 Al Ca-TRIS, before remaining
adherent cells were lysed by addition of 50 Al 1 N NaOH/
well. Finally, radioactivity of each well was measured with a
COBRA II g-Counter to quantify bound tumour cells. The
inhibition of tumour cell adhesion is expressed in percent in
comparison to control cells treated similarly but without any
addition of inhibitor.2.8. Statistics
Each in vitro experiment was done in triplicate. The
results represent the meanF S.D. of at least three indepen-
dently performed experiments. Statistical analysis was per-
formed with the unpaired Student’s t-test. Differences were
considered to be significant at P < 0.05.
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3.1. Characterisation of liposomes
The individual compositions for vesicles used in this
study are summarised in Table 1. Five different liposome
types were used in this study: plain liposome A and
sterically stabilised liposome B were prepared without sLeX
ligand, whereas liposomes C, D, and E contained 3.5 mol%
ligand conjugated to a phosphatidylethanolamine (PE)-an-
chor. Liposomes C and D contained sLeX-DSS-DMPE (M:
1671 g/mol, Fig. 1), which ensured that sLeX was closely
located to the liposomal surface because of the disuccini-
midyl suberate (DSS) spacer. Liposome D was similar to
liposome C but was prepared with additional PEG-DSPE to
obtain sterically stabilised liposomes with the ligand em-
bedded within the PEG-layer, and finally liposome E, with
sLeX-PEG-DSPE (M: f 3590 g/mol), containing the ligand
at the distant end of the long PEG spacer (Fig. 1).
3.2. Uptake of liposomes by macrophages in vitro
J774 cells were co-incubated with HPTS-containing lip-
osomes A, B and E for different times and cellular uptake
was followed to prove if the presence of the sLeX ligand at
the polyethylene chain of liposome E enhances macrophage
uptake.
Fluorescence measurements of liposomes with HPTS
allows to discriminate between total amount of vesicles
taken up by macrophages if the concentration-dependent
fluorescence at 414 nm is used, while the pH-dependent
fluorescence at 450 nm (both at 510 nm emission wave-
length) can be exploited to calculate the amount of internal-
ised liposomal HPTS in the low pH compartment of the cell
[25].
It was found that both sterically stabilised liposomes B
and E independently on the presence of the sLex-ligand
were not taken up by J774 macrophages (Table 2), whereas
plain liposome Awere taken up in a time-dependent manner
(Fig. 2). The amount of macrophage-associated lipid from
these liposomes was 5.40F 0.86 nmol/106 cells after 21 h,
50.5% of this was internalised.
3.3. Tumour cell characterisation
To select suitable tumour cell lines for inhibition experi-
ments, 14 colon, breast, lung, liver and skin tumour cell
Fig. 1. Molecular structure of the ligand sialyl-LewisX and the anchor lipid phosphatidylethanolamine. The sLeX (Neu5Aca2! 3Galh1!
4(Fuca1! 3)GlcNac)-ligand and the PE-anchor was connected covalently using the DSS spacer and the PEG-chain spacer.
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sLeX- and sLeA-equipment, using specific monoclonal anti-
bodies to recognise these ligands on the tumour cell surface.
The results for ligand-expressing cells and additionally
for Lewis lung carcinoma cells (LL) are summarised in
Table 3. Tumour cell lines were divided into cell lines with
weak, medium and strong presence of sLeX- and sLeA
ligand (Fig. 3). The colon carcinoma cell line HCT 116,
and the breast cancer cell lines MCF 7, MT1, T47D or
MDA-MB 435, all of human origin, had neither sLeX nor
sLeA ligands. For mouse cell lines B16-BL6 (melanoma),
and LL, as well as C26 (colon carcinoma), no ligand could
be detected with the specific antibodies.Table 2
Amount of liposomal lipid bound by J774 macrophages after incubation
with liposomes
Time (h) Lipid (nmol/106cells) after incubation with liposomes
A B E
0 2.65F 0.57 2.81F 0.55 3.04F 0.68
1 3.21F 0.20 1.95F 0.92 2.52F 1.00
3 3.60F 0.22 1.62F 0.90 2.17F 1.08
6 4.62F 1.04 2.12F 1.00 2.07F 0.71
21 8.05F 0.86 2.34F 0.80 2.18F 0.41
2 104 J744 mouse macrophages/well were incubated with HPTS
containing liposomes A, B and E diluted with RPMI medium/10% FCS
to a final concentration of 100 AM for indicated times at 37 jC.
Fluorescence of HPTS was determined at wavelength FEX 450 nm with
FEM at 510 nm and was used to calculate the amount of total cell associated
liposomal lipid as described in Materials and methods. It was finally
normalised to the uptake of 106 cells.3.4. Tumour cell adhesion
The adhesion of selected tumour cells was determined in
three assays, representing different E-selectin patterns: toFig. 2. Total and internal uptake of unmodified liposome A by J774
macrophages. Liposomes for macrophage uptake were prepared by
substitution of 40 mol% of PC by an equivalent molar amount of
cholesterol and resuspension of the lipid film with a 30 mM HPTS/PBS
solution, pH 7.4; 2 104 J744 mouse macrophages/well were incubated
with HPTS containing liposome A, diluted with RPMI medium (without
FCS) to a final concentration of 100 AM for indicated times at 37 jC.
Fluorescence of HPTS was determined at wavelengths FEX 414 and 450 nm
with FEM at 510 nm and was used to calculate the amount of cell associated
liposomal lipid as described in Materials and methods. It was finally
normalised to the uptake of 106 cells. The complete bars show the total
uptake of liposomal lipid and, in addition, the internalised amount of
liposomal lipid (grey parts). All data are corrected for non-specific uptake.
(*) Significantly different to uptake at each other time point ( P < 0.05).
Table 3
Characterisation of sLeX- and sLeA-ligand expression and adhesion behaviour of selected tumour cells to E-selectin targets in vitro
Cell lines Ligand equipmenta,b Binding of tumour cellsc to
Tumour
type
Name sLeX sLeA E-Selectin HUVEC CHOtransf
Colon HT29 xxx xxx 28.4F 8.1 6.7F 2.1 30.4F 6.1
LS174T xx xxx 19.6F 5.6 15.5F 3.5 n.d.
C26 z z 39.9F 7.0 12.5F 5.9 45.2F 3.6
SW480 z xx 13.4F 8.6 1.6F 0.3 n.d.
Breast MT3 xxx xxx 35.9F 12.1 8.9F 3.6 44.7F 6.8
Hepatoma HepG2 xxx x 28.7F 7.4 16.7F 2.9 36.5F 13.9
Lung LL z z 2.9F 1.2 17.2F 6.1 5.9F 2.4
n.d.: not determined.
a Ligand equipment was determined by fluorescence microscopy after treatment of cells with specific antibodies as described in Materials and methods.
s-LeA or X presence: (z) no ligand; (x) weak; (xx) medium; (xxx) strong.
b Additional cell lines investigated but were found without any s-LeA or X ligand expression were: HT116 (colon carcinoma), MCF7, MT1, T47D, MDA-
MB 435 (breast cancer), B16BL6 (melanoma).
c 51Cr-labelled tumour cells (105/well) were added to immobilised E-selectin, to endothelial cells or CHO cells for 1 h at RT. Unbound cells were washed
away and the binding was quantified by radioactivity measurements as described in Materials and methods. Given is the radioactivity of bound cells in
comparison to that of added cells in percentage meanF S.D.
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permanently express E-selectin), and to E-selectin on acti-
vated endothelial cells (Table 3).Fig. 3. Immune fluorescence of sLeX ligand expression of selected tumour cell lin
using the FITC-labelled monoclonal anti-sLeX antibody 2H5 (PharMingen Interna
and with identical sensitivity settings. Top/left: B16BL6 melanoma cells, represen
presence; bottom/left: LS174T colon carcinoma cells, medium ligand presence; bThe adhesion was dependent on the ligand expression
and, because of this, also dependent on the tumour cells. We
found adherence of tumour cells with high ligand expressiones. Cells were fluorescently labelled as described in Materials and methods
tional), diluted 1:50. All micrographs were taken with 40-fold magnification
ting no ligand presence; top/right: C26 colon carcinoma cells, weak ligand
ottom/right: MT3 breast carcinoma cells, strong ligand presence.
 
 
  
Fig. 4. Inhibition of tumour cell adhesion by sLeX ligand-bearing
liposomes. The targets were co-incubated with the inhibitors before
1105 Cr51-labelled tumour cells/well were added in each assay. Adhesion
was quantified after 1 h at RT by scintillation measurements as described in
Materials and methods. Given is the inhibition (positive values) or
stimulation (negative values) of adhesion in percentage F S.D. compared
to control (no inhibition, 0%) for HT29 colon carcinoma cells (upper panel)
and LL carcinoma cells (lower panel). Each bar indicates the mean of at
least three to four independently performed experiments each done in
R. Zeisig et al. / Biochimica et Biophysica Acta 1660 (2004) 31–40 37to be between 30% and 45% in the E selectin and CHOtransf
assay, whereas adhesion was generally lower in the HUVEC
assay (9–17%). The data obtained in the HUVEC assay
were more heterogeneous compared to those from other
systems and did not show a correlation between ligand
expression and cell adhesion.
HT29 colon carcinoma cells with high binding potential
in the E-selectin and the CHO assay and LL carcinoma cells
with weak/no ligand expression and low adhesion were
selected for the following inhibition experiments.
Cell adhesion was further determined for control reasons
by co-incubating the cells with EDTA to remove all Ca2 +
ions, which are necessary for E-selectin binding. This
completely prevents the adhesion of all tumour cells used
in the E-selectin assay (see Table 3). Results for LL and
HT29 carcinoma cells are shown in Table 4. Negative values
resulted from experiments where the (non-specific) adhe-
sion in the control experiments was higher than the adhesion
after co-incubation with inhibitor.
In addition, the specific receptor function of E-selectin
was blocked using recombinant monoclonal antibody
BBA2, which is known to bind specifically to the lectin
domain of E-selectin. Remaining adherence between 14%
and 69% for HT29 and LL cells after co-incubation with the
inhibitors suggests that additional components are likely to
be involved in mediating the adhesion between tumour and
target cells, especially to CHOtransf cells.
3.5. Inhibition of tumour cell adhesion in vitro
The inhibitory effect of glycoliposomes was determined
in all three adhesion assays and the results for HT29 colon
carcinoma (Fig. 4, upper part) and for LL cells (Fig. 4, lower
part) are shown. The inhibition experiments were always
performed with liposomes containing 3.5 nmol sLeX-ligand
per well (8.75 10 5 M).
triplicate. HT29 colon carcinoma cells: (#) significantly different to PEG-
liposomes (B) and sLex-liposomes (C) in the E-selectin assay. LL-
carcinoma cells: (*) significantly different to PEG-liposomes (B) in the E-
selectin assay, (**) significantly different to PEG-liposomes (B) in the
HUVEC assay.
Table 4
E-selectin-mediated adhesion for LL and HT29 carcinoma cells after co-
incubation with mAB BBA2 or EDTA
Adhesion (% of control)
Assay BBA2 EDTA
Cells LL HT29 LL HT29
E-Selectin 14.4F 15.2 28.6F 6.9  7.8F 14.4 1.1F1.4
CHOtransf 46.7F 19.8 68.8F 14.5 26.8F 14.6 3.5F 1.2
HUVEC 28.2F 25.3 48.9F 37.6  19.4F 45.5  25.8F 36.1
51Cr-sodium chromate labelled tumour cells were added to immobilised hu
E-selectin, CHOtransf or HUVEC cells in the presence of mAB BBA2 or
EDTA and the remaining tumour cell adhesion was determined by
measurement of radioactivity of bound cells as described in Materials
and methods.
Adhesion (A) was calculated as follows: A (%)=[RxRunspec]/[Rtot
Runspec] 100; Rx radioactivity of test cells, Runspec: radioactivity of non-
specific bound cells, Rtot: radioactivity of cells incubated without inhibitor.
Results represent the mean adhesion F S.D. after co-incubation with the
inhibitor in comparison to untreated tumour cells for four to five
independently performed experiments, each done in triplicate.Ligand-free liposomes A and B had no significant
influence on the adhesion of HT29 or LL cells; values
varied around zero. In some cases, adhesion was rather
stimulated. SLex-PEG liposome E inhibited the adhesion of
both cell lines in all three assays used up to 80%. A similar
or only slightly lower inhibition was also obtained with
ligand-bearing but not sterically stabilised liposome C and
liposome D containing the ligand within the PEG-layer.
It is further obvious that the strongest inhibition was
obtained in the assay with immobilised E-selectin. Interest-
ingly, focussing on the adhesion of HT29 cells to HUVECs,
which is the best mimicking model for interaction of human
tumour cells with vascular endothelial cells, only liposome
E lead to an inhibition of binding while all other liposomes
rather stimulate adhesion.
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The aim of this study was to directly compare for the first
time glycoliposomes that differ in the accessibility of the
sLex ligand and in sterical stabilisation for their potency to
inhibit competitively the E-selectin-mediated tumour cell
adhesion in vitro.
It was already shown earlier that liposomes are suitable
vesicles to block the adhesion process [11,21,22]. Lip-
osomes have the advantage of an especially high flexibility
of the liposomal bilayer. Because of this, ligands at their
surface are able to form clusters and to fulfil in this way the
requirement for a multivalent ligand interaction [21].
To obtain an efficient binding between the liposomes and
E-selectin at the endothelial site, the tetrasaccharide sLeX
was chosen as a well-known ligand for this receptor [27].
Glycoliposomes with this ligand, on the other hand, also
competitively prevent the binding of other ligands for E-
selectin at the same time, for example of sLeA, which can
additionally be present at the membranes of some tumour
cells.
In a first experiment, we quantified the effect of sterical
stabilisation on cellular uptake by macrophages in the
absence and presence of the ligand to make sure that the
uptake of investigated ligand decorated liposomes by the
monocyte/phagocytic system (MPS) will be reduced or
prevented in future animal experiments. It is well known
that liposomes which are covered by PEG chains (called
sterically stabilised or PEG-liposomes) have a prolonged
circulation in the bloodstream because of the ‘‘stealth’’
effect and the resulting decrease in the uptake by the MPS
[28,29]. Liposomes with a modified surface like immuno- or
glycoliposomes, but without a sterical stabilisation, are very
likely to be taken up by the MPS [30,31]. In addition, the
presence of a ligand together with a PEG cover can also
enhance uptake [32,33]. Thus, the uptake of liposome E was
quantified in a time dependent way in comparison to
liposome A (unmodified surface) and liposome B (sterically
stabilised without ligand). Only liposome A was taken up
and internalised by J774 cells in vitro in a time-dependent
way (Fig. 2), whereas sterically stabilised liposomes were
not (Table 2), indicating that liposome E is suitable for in
vivo applications.
In the next step, we characterised the sLeX/A ligand
expression of different human and murine tumour cell lines.
Based on this, cells which differently expressed the ligands
were selected for quantification of adhesion. Therefore,
three static assays were used. Adhesion of tumour cells to,
first, immobilised E-selectin, second, to CHOtransf cells,
transfected to express permanently E-selectin, and third, to
the endothelial cells HUVEC, was determined.
Most of the investigated tumour cell lines (like HT29,
SW480, MT3 and HepG2) adhered similarly in all three
assays, showing a strong adhesion in the E-selectin and
CHO assay and a weaker binding in the HUVEC assay. The
low adhesion to endothelial cells may be caused by thelower number of cells used in this assay because of the
larger size of the HUVEC cells. In contrast to this, LL cells
were found to adhere to a lower degree in the E-selectin and
CHO assay, but to a higher degree in the HUVEC assay.
This suggests especially for LL cells, that not only the
interaction between sLeX and sLeA with E-selectin deter-
mines the adhesion to HUVEC cells. The involvement of
other ligand/receptor combinations between tumour and
target cells could be responsible for the increase observed
for LL cell adhesion. This was confirmed by quantification
of the specific adhesion to E-selectin using the inhibitor
BBA2, a monoclonal antibody which specifically recognises
human E-selectin, and EDTA, which removes Ca2 +, a
cation necessary for E-selectin binding (Table 4). The
binding to immobilised E-selectin could be reduced to
14–29% under standard conditions and completely if the
concentration of the antibody was increased (data not
shown). The remaining binding of tumour cells to CHO-
and HUVEC cells of 28–69% after co-incubation with the
BBA2 antibody suggests the partial involvement of addi-
tional binding sites like integrins or mucins [33–35] in a
cell line-dependent way in the interaction between tumour
cells and the endothelial surface.
The inhibition of tumour cell adhesion by the different
liposomes was performed with selected tumour cell lines in
all three assays in vitro and results are shown for HT29
colon carcinoma cells as well as for LL carcinoma cells
(Fig. 4).
As expected, glycoliposome C and sLeX-PEG-liposome
E had in general the highest inhibitory potential. The
inhibition was dependent on the concentration of the lip-
osomes, the adhesion assay and on the cell line used.
Liposome E inhibited the adhesion of tumour cells to E-
selectin up to 80% (or up to 40–60% in the HUVEC assay).
This demonstrated that the PEG layer had no restrictive
influence on the binding ability of the terminal sLeX group,
or could even enhance the inhibition compared to vesicles C
probably because of the high flexibility of this ligand
construct.
In contrast, glycoliposome D with the sLeX ligand
embedded within the PEG layer, had a lower inhibition
potency, suggesting that the accessibility of the ligand was
reduced by the PEG layer.
While liposome E had a strong inhibitory effect on the
adhesion of both cell lines in the HUVEC assay, liposomes
A–D seem to cause an increase in HT29 cell adhesion in
this assay, but related to the strong variation between the
different experiments, this conclusion still has to be proved.
If there is an enhancement of adhesion, an (non-specific)
attraction between the colon carcinoma and the endothelial
cells could be responsible for this, which is not related to E-
selectin. All ligand-bearing liposomes used in other assays
inhibited HT29 cell adhesion, and in addition, all LL cell
binding in any assay.
To summarise our results, it was found that sLeX-
equipped liposomes are an interesting tool for the inhibition
R. Zeisig et al. / Biochimica et Biophysica Acta 1660 (2004) 31–40 39of the adhesion between tumour cells and targets with E-
selectin as receptor. Based on the systematic investigation of
different liposomal preparations concerning their adhesion
inhibition potency, this study revealed that sterically stabi-
lised liposomes with the sLeX ligand at the distal end of a
PEG chain (sLeX-PEG-liposome E) had the most powerful
inhibitory potency in static adhesion assays in vitro. Addi-
tionally taking into account that these liposomal formula-
tions are not taken up by macrophages, in vivo experiments
are warranted with these liposomes and will be performed.Acknowledgements
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